[FG] Läubli Heinz

Filipsky, F. and Läubli, H. (2024) ‘Regulation of sialic acid metabolism in cancer’, Carbohydrate Research, 539. Available at: https://doi.org/10.1016/j.carres.2024.109123.

Amaral, Margarida et al. (2024) ‘Paraneoplastic subacute cutaneous lupus erythematosus’, Dermatologie [Preprint]. Available at: https://doi.org/10.1007/s00105-024-05319-6.

Brune, Magdalena M. et al. (2024) ‘MTAP as an emerging biomarker in thoracic malignancies’, Lung Cancer, 197. Available at: https://doi.org/10.1016/j.lungcan.2024.107963.

Chu, Chih-Wei et al. (2024) ‘Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors’, Life Science Alliance, 7. Available at: https://doi.org/10.26508/lsa.202302368.

Daetwyler, Eveline et al. (2024) ‘Corticosteroid-resistant immune-related adverse events: A systematic review’, Journal for ImmunoTherapy of Cancer, 12. Available at: https://doi.org/10.1136/jitc-2023-007409.

De Joode, Karlijn et al. (2024) ‘Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients with Advanced Stage Melanoma’, Journal of Immunotherapy, 47, pp. 190–194. Available at: https://doi.org/10.1097/CJI.0000000000000506.

Freitag, Patrick C. et al. (2024) ‘DARPin-fused T cell engager for adenovirus-mediated cancer therapy’, Molecular Therapy Oncology, 32. Available at: https://doi.org/10.1016/j.omton.2024.200821.

König, David et al. (2024) ‘Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes’, Cancer Immunology Research, 12, pp. 814–821. Available at: https://doi.org/10.1158/2326-6066.CIR-23-0757.

König, D. et al. (2024) ‘Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma’, Immuno-Oncology and Technology [Preprint]. Available at: https://doi.org/10.1016/j.iotech.2024.100728.

Läubli, Heinz (2024) ‘Unraveling the impact of a glyco-immune checkpoint in bone metastasis’, Proceedings of the National Academy of Sciences of the United States of America, 121. Available at: https://doi.org/10.1073/pnas.2400499121.

Mangana, Johanna et al. (2024) ‘Gender differences in melanoma awareness, diagnosis and treatment: Patient-reported data from a multicentre survey in Switzerland’, Skin Health and Disease, 4. Available at: https://doi.org/10.1002/ski2.442.

Mantuano, Natalia Rodrigues and Läubli, Heinz (2024) ‘Sialic acid and Siglec receptors in tumor immunity and immunotherapy’, Seminars in Immunology, 74-75. Available at: https://doi.org/10.1016/j.smim.2024.101893.

Märkl, Florian et al. (2024) ‘Mutation-specific CAR T cells as precision therapy for IGLV3-21 R110 expressing high-risk chronic lymphocytic leukemia’, Nature Communications, 15. Available at: https://doi.org/10.1038/s41467-024-45378-w.

Martins, Tomás A. et al. (2024) ‘Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker’, Nature Communications, 15(1). Available at: https://doi.org/10.1038/s41467-024-54129-w.

Mastall, Maximilian et al. (2024) ‘A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol’, BMC Cancer, 24. Available at: https://doi.org/10.1186/s12885-023-11797-z.

Melero, Ignacio et al. (2024) ‘Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours’, Nature [Preprint]. Available at: https://doi.org/10.1038/s41586-024-08305-z.

Saalfeld, Felix Carl et al. (2024) ‘Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy’, European Journal of Cancer, 213. Available at: https://doi.org/10.1016/j.ejca.2024.115065.

Stadler, Christina et al. (2024) ‘Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older’, Neuro-Oncology Practice, 11, pp. 132–141. Available at: https://doi.org/10.1093/nop/npad070.

Tundo, Sofia et al. (2024) ‘Inhibition of Cbl-b restores effector functions of human intratumoral NK cells’, Journal for immunotherapy of cancer, 12. Available at: https://doi.org/10.1136/jitc-2024-009860.

Wieboldt, Ronja et al. (2024) ‘Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2’, Cellular and Molecular Immunology, null. Available at: https://doi.org/10.1038/s41423-024-01142-0.

Wyss, Nina et al. (2024) ‘Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade’, American Journal of Respiratory and Critical Care Medicine, 210, pp. 919–930. Available at: https://doi.org/10.1164/rccm.202311-2136OC.

Bieberich, F. et al. (2023) Multimodal single-cell profiling of T cell specificity and reactivity in lung cancer. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.10.04.560863.

Schumann K et al. (2023) ‘Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.’, Journal of the European Academy of Dermatology and Venereology : JEADV, 37(5), pp. 894–906. Available at: https://doi.org/10.1111/jdv.18779.

Stanczak MA and Läubli H (2023) ‘Siglec receptors as new immune checkpoints in cancer.’, Molecular aspects of medicine, 90, p. 101112. Available at: https://doi.org/10.1016/j.mam.2022.101112.

Conti, Gabriele et al. (2023) ‘Tetra- and Hexavalent Siglec-8 Ligands Modulate Immune Cell Activation’, Angewandte Chemie - International Edition. 09.11.2023, 62(52). Available at: https://doi.org/10.1002/anie.202314280.

Daetwyler, Eveline et al. (2023) ‘Pembrolizumab-induced optic neuropathy – a case report’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1171981.

Joerger, Markus et al. (2023) ‘Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors’, Journal for ImmunoTherapy of Cancer, 11. Available at: https://doi.org/10.1136/jitc-2023-007784.

König, D. et al. (2023) ‘Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14’, ESMO Open, 8(4), p. 101595. Available at: https://doi.org/10.1016/j.esmoop.2023.101595.

Läubli, H. (2023) ‘Cellular immunotherapies for malignancies - How do they work and what are the side effects?’, Therapeutische Umschau. Revue therapeutique, 80, pp. 348–352.

Manni, Michela et al. (2023) ‘Detection of N-glycolyl-neuraminic acid-containing glycolipids in human skin’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1291292.

Müller, Benjamin et al. (2023) ‘Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events’, Frontiers in Immunology, 14. Available at: https://doi.org/10.3389/fimmu.2023.1125111.

Pedram, K. et al. (2023) ‘Design of a mucin-selective protease for targeted degradation of cancer-associated mucins’, Nature Biotechnology, null. Available at: https://doi.org/10.1038/s41587-023-01840-6.

Puttock, E.H. et al. (2023) ‘Extracellular matrix educates an immunoregulatory tumor macrophage phenotype found in ovarian cancer metastasis’, Nature Communications, 14. Available at: https://doi.org/10.1038/s41467-023-38093-5.

Schmassmann, P. et al. (2023) ‘Targeting the Siglec–sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma’, Science Translational Medicine, 15. Available at: https://doi.org/10.1126/scitranslmed.adf5302.

Wallrabenstein, Till et al. (2023) ‘Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study’, JTO Clinical and Research Reports, 4(5), p. 100509. Available at: https://doi.org/10.1016/j.jtocrr.2023.100509.

Läubli H, Nalle SC and Maslyar D (2022) ‘Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches.’, Cancer immunology research, 10(12), pp. 1423–1432. Available at: https://doi.org/10.1158/2326-6066.cir-22-0366.

Panje C et al. (2022) ‘Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.’, European journal of cancer (Oxford, England : 1990), 177, pp. 186–193. Available at: https://doi.org/10.1016/j.ejca.2022.09.035.

Kirchhammer N et al. (2022) ‘Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment.’, Science translational medicine, 14(670), p. eabo3605. Available at: https://doi.org/10.1126/scitranslmed.abo3605.

Castellanos-Rueda R et al. (2022) ‘speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing.’, Nature communications, 13(1), p. 6555. Available at: https://doi.org/10.1038/s41467-022-34141-8.

Stanczak MA et al. (2022) ‘Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.’, Science translational medicine, 14(669), p. eabj1270. Available at: https://doi.org/10.1126/scitranslmed.abj1270.

Vazquez-Lombardi R et al. (2022) ‘High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.’, Immunity, 55(10), pp. 1953–1966.e10. Available at: https://doi.org/10.1016/j.immuni.2022.09.004.

Berner F et al. (2022) ‘Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.’, Science immunology, 7(75), p. eabn9644. Available at: https://doi.org/10.1126/sciimmunol.abn9644.

Zeitlberger AM et al. (2022) ‘Next generation sequencing in adult patients with glioblastoma in Switzerland: a multi-centre decision analysis.’, Journal of neuro-oncology, 158(3), pp. 359–367. Available at: https://doi.org/10.1007/s11060-022-04022-7.

Wieboldt R and Läubli H (2022) ‘Glycosaminoglycans in cancer therapy.’, American journal of physiology. Cell physiology, 322(6), pp. C1187–C1200. Available at: https://doi.org/10.1152/ajpcell.00063.2022.

Kostner L et al. (2022) ‘Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown.’, Cancers, 14(10). Available at: https://doi.org/10.3390/cancers14102360.

Beatson R et al. (2022) ‘Editorial: Glycans: Masters of immunity, from cancers to inflammatory disease.’, 13. Available at: https://doi.org/10.3389/fimmu.2022.1002679.

Kasenda, B. et al. (2022) ‘Targeting immunoliposomes to EGFR-positive glioblastoma’, ESMO Open, 7. Available at: https://doi.org/10.1016/j.esmoop.2021.100365.

Kaumanns, Anna et al. (2022) ‘Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study’, Lung Cancer, 173, pp. 14–20. Available at: https://doi.org/10.1016/j.lungcan.2022.08.020.

König, David et al. (2022) ‘Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma’, Pharmacology, 107, pp. 433–438. Available at: https://doi.org/10.1159/000524399.

König, D. et al. (2022) ‘Corrigendum to ‘Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials’: [ESMO Open Volume 7, Issue 2, (2022), 100455](S2059702922000710)(10.1016/j.esmoop.2022.100455)’, ESMO Open, 7(3), p. 100494. Available at: https://doi.org/10.1016/j.esmoop.2022.100494.

König, D. et al. (2022) ‘Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials’, ESMO Open, 7. Available at: https://doi.org/10.1016/j.esmoop.2022.100455.

Läubli, H. and Zippelius, A. (2022) ‘Tumor-infiltrating lymphocytes (TIL) therapy for malignant melanoma’, Tagliche Praxis, 65, pp. 620–629.

Mandruzzato S and Läubli H (2022) ‘Editorial: Novel roles for tumor-associated neutrophils.’, 13. Available at: https://doi.org/10.3389/fimmu.2022.1004772.

Ruperti-Repilado, Francisco Javier et al. (2022) ‘Case report of elevation of high-sensitivity cardiac troponin T in the absence of cardiac involvement in immune checkpoint inhibitor-associated myositis’, European Heart Journal - Case Reports, 6(9), p. ytac353. Available at: https://doi.org/10.1093/ehjcr/ytac353.

Wang, Jinyu et al. (2022) ‘Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer’, Frontiers in Cell and Developmental Biology, 10. Available at: https://doi.org/10.3389/fcell.2022.828916.

Laubli H. et al. (2021) ‘Tools to study and target the Siglec–sialic acid axis in cancer’, FEBS Journal, 288(21), pp. 6206–6225. Available at: https://doi.org/10.1111/febs.15647.

Werner F. et al. (2021) ‘Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma.’, Diagnostics (Basel, Switzerland), 11(7). Available at: https://doi.org/10.3390/diagnostics11071238.

Hofer S et al. (2021) ‘Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM).’, Swiss medical weekly, 151, p. w20501. Available at: https://doi.org/10.4414/smw.2021.20501.

Gross MW, Laubli H. and Cordier D (2021) ‘Multidisciplinary tumor boards as videoconferences - a new challenge in the COVID-19 era.’, 32(4). Available at: https://doi.org/10.1016/j.annonc.2021.01.002.

Kelly RJ et al. (2021) ‘Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.’, The New England journal of medicine, 384(13), pp. 1191–1203. Available at: https://doi.org/10.1056/nejmoa2032125.

Pantelyushin S. et al. (2021) ‘Cross-reactivity and functionality of approved human immune checkpoint blockers in dogs’, Cancers, 13(4), pp. 1–18. Available at: https://doi.org/10.3390/cancers13040785.

Läubli, H. and Zippelius, A. (2021) ‘Tumor-infiltrating lymphocytes (TIL) therapy for malignant melanoma’, Internistische Praxis, 64, pp. 456–464.

Manni M. and Laubli H. (2021) ‘Targeting glyco-immune checkpoints for cancer therapy’, Expert Opinion on Biological Therapy, 21(8), pp. 1063–1071. Available at: https://doi.org/10.1080/14712598.2021.1882989.

Werner F. et al. (2021) ‘A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration.’, Frontiers in immunology, 12, p. 675146. Available at: https://doi.org/10.3389/fimmu.2021.675146.

Gray MA et al. (2020) ‘Targeted glycan degradation potentiates the anticancer immune response in vivo.’, Nature chemical biology, 16(12), pp. 1376–1384. Available at: https://doi.org/10.1038/s41589-020-0622-x.

Pearce O.M.T. and Laubli H. (2020) ‘A sweet approach to heat up cancer response to immunotherapy’, Cancer Discovery, 10(12), pp. 1789–1790. Available at: https://doi.org/10.1158/2159-8290.cd-20-1355.

Rodrigues Mantuano N et al. (2020) ‘Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy.’, Journal for immunotherapy of cancer, 8(2). Available at: https://doi.org/10.1136/jitc-2020-001222.

Rodrigues Mantuano N et al. (2020) ‘Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation.’, Cancer immunology research, 8(10), pp. 1262–1272. Available at: https://doi.org/10.1158/2326-6066.cir-19-0904.

Trefny MP et al. (2020) ‘PD-1(+) natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade.’, Cancer immunology, immunotherapy : CII, 69(8), pp. 1505–1517. Available at: https://doi.org/10.1007/s00262-020-02558-z.

Trüb M et al. (2020) ‘Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.’, Journal for immunotherapy of cancer, 8(2). Available at: https://doi.org/10.1136/jitc-2019-000238.

Roth P et al. (2020) ‘A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults’, Swiss Medical Weekly, 150(23-24). Available at: https://doi.org/10.4414/smw.2020.20256.

Fehr M et al. (2020) ‘High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.’, BMC cancer, 20(1), p. 166. Available at: https://doi.org/10.1186/s12885-020-6623-z.

Läubli H and Varki A (2020) ‘Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.’, Cellular and molecular life sciences : CMLS, 77(4), pp. 593–605. Available at: https://doi.org/10.1007/s00018-019-03288-x.

Alborelli I et al. (2020) ‘Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.’, The Journal of pathology, 250(1), pp. 19–29. Available at: https://doi.org/10.1002/path.5344.

Trinh B, Donath MY and Läubli H (2020) ‘Response to Comment on Trinh et al. Successful Treatment of Immune Checkpoint Inhibitor-Induced Diabetes With Infliximab. Diabetes Care 2019;42:e153-e154.’, 43(1). Available at: https://doi.org/10.2337/dci19-0058.

Ortega Sanchez G et al. (2019) ‘Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation.’, Swiss medical weekly, 149, p. w20150. Available at: https://doi.org/10.4414/smw.2019.20150.

Bärenwaldt A and Läubli H (2019) ‘The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.’, Expert opinion on therapeutic targets. 23.09.2019, 23(10), pp. 839–853. Available at: https://doi.org/10.1080/14728222.2019.1667977.

Liewen H et al. (2019) ‘Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX).’, Targeted oncology, 14(5), pp. 577–590. Available at: https://doi.org/10.1007/s11523-019-00667-z.

Kashyap AS et al. (2019) ‘GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses.’, Cell reports, 28(13), pp. 3367–3380.e8. Available at: https://doi.org/10.1016/j.celrep.2019.08.057.

Griss J et al. (2019) ‘B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma.’, Nature communications, 10(1), p. 4186. Available at: https://doi.org/10.1038/s41467-019-12160-2.

Trinh B, Donath MY and Läubli H (2019) ‘Successful treatment of immune checkpoint inhibitor-induced diabetes with infliximab’, 42(9). Available at: https://doi.org/10.2337/dc19-0908.

Berner F et al. (2019) ‘Association of Checkpoint Inhibitor-Induced Toxic Effects with Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer’, JAMA Oncology, 5(7), pp. 1043–1047. Available at: https://doi.org/10.1001/jamaoncol.2019.0402.

Haas Q et al. (2019) ‘Siglec-9 Regulates an Effector Memory CD8þ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment’, Cancer Immunology Research, 7(5), pp. 707–718. Available at: https://doi.org/10.1158/2326-6066.cir-18-0505.

Streckmann F et al. (2019) ‘Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial-VANISH.’, BMJ open, 9(4), p. e024467. Available at: https://doi.org/10.1136/bmjopen-2018-024467.

Cheng WC et al. (2019) ‘Publisher Correction: Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.’, 20(4). Available at: https://doi.org/10.1038/s41590-019-0359-4.

Läubli H, Dirnhofer S and Zippelius A (2019) ‘Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy’, Virchows Archiv. 25.08.2018, 474(4), pp. 485–495. Available at: https://doi.org/10.1007/s00428-018-2435-9.

Trinh B et al. (2019) ‘Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma’, Journal for ImmunoTherapy of Cancer, 7(1), p. 52. Available at: https://doi.org/10.1186/s40425-019-0528-x.

Cheng WC et al. (2019) ‘Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle’, Nature Immunology, 20(2), pp. 206–217. Available at: https://doi.org/10.1038/s41590-018-0290-0.

Grossert, Astrid et al. (2019) ‘A clinical trial of group-based body psychotherapy to improve bodily disturbances in post-treatment cancer patients in combination with randomized controlled smartphone-triggered bodily interventions (KPTK): study protocol’, BMC psychology, 7(1), p. 90. Available at: https://doi.org/10.1186/s40359-019-0357-1.

Läubli H and Borsig L (2019) ‘Altered Cell Adhesion and Glycosylation Promote Cancer Immune Suppression and Metastasis.’, Frontiers in immunology, 10, p. 2120. Available at: https://doi.org/10.3389/fimmu.2019.02120.

Trefny MP et al. (2019) ‘A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer’, Clinical Cancer Research, 25(10), pp. 3026–3034. Available at: https://doi.org/10.1158/1078-0432.ccr-18-3041.

Stanczak, Michal A et al. (2018) ‘Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.’, The Journal of clinical investigation. 24.09.2018, 128(11), pp. 4912–4923. Available at: https://doi.org/10.1172/jci120612.

Ortega Sanchez G et al. (2018) ‘Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.’, Journal for immunotherapy of cancer, 6(1), p. 85. Available at: https://doi.org/10.1186/s40425-018-0400-4.

Adams OJ et al. (2018) ‘Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.’, Glycobiology, 28(9), pp. 640–647. Available at: https://doi.org/10.1093/glycob/cwx108.

Pearce OMT and Läubli H (2018) ‘Cancer Immunotherapy.’, Glycobiology, 28(9), pp. 638–639. Available at: https://doi.org/10.1093/glycob/cwy069.

Ruhstaller T et al. (2018) ‘Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).’, Annals of oncology : official journal of the European Society for Medical Oncology, 29(6), pp. 1386–1393. Available at: https://doi.org/10.1093/annonc/mdy105.

Wicki A et al. (2018) ‘First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).’, European journal of cancer (Oxford, England : 1990), 96, pp. 6–16. Available at: https://doi.org/10.1016/j.ejca.2018.03.012.

Läubli, Heinz et al. (2018) ‘Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.’, Journal for immunotherapy of cancer, 6(1), p. 40. Available at: https://doi.org/10.1186/s40425-018-0353-7.

Borsig L. and Laubli H. (2018) ‘Cell adhesion during tumorigenesis and metastasis’. Elsevier, pp. 307–314. Available at: https://doi.org/10.1016/b978-0-12-801238-3.64991-7.

Läubli H et al. (2018) ‘The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors.’, Oncoimmunology. 26.10.2017, 7(2), p. e1386362. Available at: https://doi.org/10.1080/2162402x.2017.1386362.